Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: In children below 12 yr of age, hemoglobin A1c (HbA1c) at start was 8.3 +/- 0.8% and after 12 months of treatment with insulin detemir significantly lowered (7.6 +/- 0.6%, p < 0.001). In the age-group above 12 yr of age at the start of the study, the improvement of HbA1c after 12 months of treatment was less pronounced (8.0 +/- 1.2 vs. 7.6 +/- 1.0%) but still significant (p < 0.01). The risk for severe hypoglycemia was significantly decreased compared with patients attending the outpatient clinic between 1995 and 2003 (4.8/100 patient years vs. 7.6/100 patient years, p = 0.003). From the beginning to the end of the follow-up period, body mass index dropped significantly in children below 12 yr of age but no effect was observed in adolescents. CONCLUSIONS:
|
Authors | Doris Braun, Daniel Konrad, Mariarosaria Lang-Muritano, Eugen Schoenle |
Journal | Pediatric diabetes
(Pediatr Diabetes)
Vol. 9
Issue 4 Pt 2
Pg. 382-7
(Aug 2008)
ISSN: 1399-5448 [Electronic] Denmark |
PMID | 18331413
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Insulin, Long-Acting
- Insulin Detemir
|
Topics |
- Adolescent
- Blood Glucose
(analysis)
- Child
- Diabetes Mellitus, Type 1
(blood, drug therapy)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypoglycemia
(blood, chemically induced)
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Insulin
(adverse effects, analogs & derivatives, therapeutic use)
- Insulin Detemir
- Insulin, Long-Acting
- Male
- Retrospective Studies
- Severity of Illness Index
|